Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation
The occurrence of SOX2-specific autoantibodies seems to be associated with an improved prognosis in patients with monoclonal gammopathy of undetermined significance (MGUS). However, it is unclear if SOX2-specific antibodies also develop in established multiple myeloma (MM). Screening 1094 peripheral...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/302145 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308093850058752 |
|---|---|
| author | Sebastian Kobold Sinje Tams Tim Luetkens Yanran Cao Orhan Sezer Britta Marlen Bartels Henrike Reinhard Julia Templin Katrin Bartels York Hildebrandt Nesrine Lajmi Andreas Marx Friedrich Haag Carsten Bokemeyer Nicolaus Kröger Djordje Atanackovic |
| author_facet | Sebastian Kobold Sinje Tams Tim Luetkens Yanran Cao Orhan Sezer Britta Marlen Bartels Henrike Reinhard Julia Templin Katrin Bartels York Hildebrandt Nesrine Lajmi Andreas Marx Friedrich Haag Carsten Bokemeyer Nicolaus Kröger Djordje Atanackovic |
| author_sort | Sebastian Kobold |
| collection | DOAJ |
| description | The occurrence of SOX2-specific autoantibodies seems to be associated with an improved prognosis in patients with monoclonal gammopathy of undetermined significance (MGUS). However, it is unclear if SOX2-specific antibodies also develop in established multiple myeloma (MM). Screening 1094 peripheral blood (PB) sera from 196 MM patients and 100 PB sera from healthy donors, we detected SOX2-specific autoantibodies in 7.7% and 2.0% of patients and donors, respectively. We identified SOX2211–230 as an immunodominant antibody-epitope within the full protein sequence. SOX2 antigen was expressed in most healthy tissues and its expression did not correlate with the number of BM-resident plasma cells. Accordingly, anti-SOX2 immunity was not related to SOX2 expression levels or tumor burden in the patients’ BM. The only clinical factor predicting the development of anti-SOX2 immunity was application of allogeneic stem cell transplantation (alloSCT). Anti-SOX2 antibodies occurred more frequently in patients who had received alloSCT (n=74). Moreover, most SOX2-seropositive patients had only developed antibodies after alloSCT. This finding indicates that alloSCT is able to break tolerance towards this commonly expressed antigen. The questions whether SOX2-specific autoantibodies merely represent an epiphenomenon, are related to graft-versus-host effects or participate in the immune control of myeloma needs to be answered in prospective studies. |
| format | Article |
| id | doaj-art-1340e985962c441bb5cef8f5304ff6f5 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-1340e985962c441bb5cef8f5304ff6f52025-08-20T03:54:33ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/302145302145Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell TransplantationSebastian Kobold0Sinje Tams1Tim Luetkens2Yanran Cao3Orhan Sezer4Britta Marlen Bartels5Henrike Reinhard6Julia Templin7Katrin Bartels8York Hildebrandt9Nesrine Lajmi10Andreas Marx11Friedrich Haag12Carsten Bokemeyer13Nicolaus Kröger14Djordje Atanackovic15Department of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyInstitute for Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyInstitute for Immunology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyThe occurrence of SOX2-specific autoantibodies seems to be associated with an improved prognosis in patients with monoclonal gammopathy of undetermined significance (MGUS). However, it is unclear if SOX2-specific antibodies also develop in established multiple myeloma (MM). Screening 1094 peripheral blood (PB) sera from 196 MM patients and 100 PB sera from healthy donors, we detected SOX2-specific autoantibodies in 7.7% and 2.0% of patients and donors, respectively. We identified SOX2211–230 as an immunodominant antibody-epitope within the full protein sequence. SOX2 antigen was expressed in most healthy tissues and its expression did not correlate with the number of BM-resident plasma cells. Accordingly, anti-SOX2 immunity was not related to SOX2 expression levels or tumor burden in the patients’ BM. The only clinical factor predicting the development of anti-SOX2 immunity was application of allogeneic stem cell transplantation (alloSCT). Anti-SOX2 antibodies occurred more frequently in patients who had received alloSCT (n=74). Moreover, most SOX2-seropositive patients had only developed antibodies after alloSCT. This finding indicates that alloSCT is able to break tolerance towards this commonly expressed antigen. The questions whether SOX2-specific autoantibodies merely represent an epiphenomenon, are related to graft-versus-host effects or participate in the immune control of myeloma needs to be answered in prospective studies.http://dx.doi.org/10.1155/2011/302145 |
| spellingShingle | Sebastian Kobold Sinje Tams Tim Luetkens Yanran Cao Orhan Sezer Britta Marlen Bartels Henrike Reinhard Julia Templin Katrin Bartels York Hildebrandt Nesrine Lajmi Andreas Marx Friedrich Haag Carsten Bokemeyer Nicolaus Kröger Djordje Atanackovic Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation Clinical and Developmental Immunology |
| title | Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation |
| title_full | Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation |
| title_fullStr | Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation |
| title_full_unstemmed | Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation |
| title_short | Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation |
| title_sort | patients with multiple myeloma develop sox2 specific autoantibodies after allogeneic stem cell transplantation |
| url | http://dx.doi.org/10.1155/2011/302145 |
| work_keys_str_mv | AT sebastiankobold patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT sinjetams patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT timluetkens patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT yanrancao patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT orhansezer patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT brittamarlenbartels patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT henrikereinhard patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT juliatemplin patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT katrinbartels patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT yorkhildebrandt patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT nesrinelajmi patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT andreasmarx patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT friedrichhaag patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT carstenbokemeyer patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT nicolauskroger patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation AT djordjeatanackovic patientswithmultiplemyelomadevelopsox2specificautoantibodiesafterallogeneicstemcelltransplantation |